The FDA’s recent announcement signals that, in many cases, one well-designed pivotal trial may serve as the default pathway for approval, replacing the previous expectation of two adequate and well-controlled Phase 3 studies. Earlier development phases remain part of the process. What changes is the evidentiary standard at the pivotal stage. Regulators have framed this shift as enabled by advances in precision medicine and better trial design, arguing that for targeted therapies and high unmet need populations, a single rigorous study can generate sufficient evidence for decision-making when supported by confirmatory data.

In practice, this trajectory has already been unfolding. A significant share of recent new drug approvals have relied on a single pivotal study, often through accelerated pathways. What changes now is not the existence of the single pivotal trial model, but its expansion across therapeutic areas beyond oncology and rare disease.

This is a consequential change.

For companies that historically expected to run two large Phase 3 trials, the implications are significant. Designing one rigorous study capable of supporting approval will reduce duplication, lower development costs, and shorten timelines. These changes will benefit patients by addressing one of the industry’s most frequently cited drivers of rising drug prices.

Where the Clarification May Matter Most

By describing one pivotal study as the default evidentiary pathway in appropriate contexts, the FDA is providing sponsors with greater predictability in development planning and opening the door for broader use of single-trial strategies across therapeutic areas where single-trial approvals have historically been uncommon.

Accelerated approval pathways have long supported oncology, rare diseases, and therapies targeting underserved populations. Analysts suggest the FDA’s clarification could encourage broader use of single-pivotal-trial strategies in areas such as:

• Ophthalmology
• Psychiatry
• Immunology
• Cardiovascular disease

For sponsors in these areas, the possibility of a single pivotal trial creates an opportunity to rethink development strategies.

Rather than designing programs around sequential confirmatory studies, teams may increasingly focus on building one highly rigorous, well-powered trial capable of supporting regulatory decision-making when combined with complementary evidence.

Confirmatory support may come from multiple sources, including mechanistic science, related indications, real-world evidence, or additional clinical studies conducted before or after approval.

‘One Trial’ Requires Continuous Trial Intelligence

The ‘One Trial’ shift exposes the absence of a seamless operational layer between trial execution and regulatory engagement. Several structural gaps stand out:

• Capital compression. A single pivotal trial means that larger investments may be committed earlier in development. Teams will need embedded decision gates supported by real-time safety, enrollment, and endpoint monitoring to manage that risk responsibly.

• Operational continuity. With the entire success of the asset relying now on a single pivotal study, the cost of episodic data review increases. Delays in reconciling data across EDC, CTMS, labs, imaging, and safety systems introduce risks that are difficult to recover from within a single study.‍

• Regulatory defensibility. When approval rests on a single pivotal study, transparency becomes more important than ever. Interim adaptations, safety signals, and execution decisions should be explainable and audit-ready, supported by unified data throughout the trial.

• Post-approval expectations. The FDA has signaled a growing role for real-world evidence after approval. Sponsors that build continuity between their trial execution environment and post-market follow-up will be better positioned to meet that expectation.

Most clinical trial infrastructure was not designed for this continuous model.

Critical data streams remain fragmented across EDC platforms, CTMS systems, safety databases, imaging vendors, laboratories, and digital endpoint providers. Reconciliation and analysis often occur periodically rather than continuously.

When development programs rely on multiple trials, this episodic model is manageable. When the evidentiary foundation rests heavily on a single pivotal study, the tolerance for delayed insight shrinks.

Sponsors increasingly need the ability to:

• Detect emerging safety imbalance early
• Identify enrollment drift or site-level risk
• Monitor endpoint quality and protocol adherence
• Understand operational deviations before they compromise evidence generation

In short, they need continuous visibility into the health of the trial while it is still possible to intervene.

The Path Forward

In a ‘One Trial’ world, periodic interim analyses and database lock cannot be the sole moments of clarity in a trial. Evidence must be continuously captured and translated into knowledge in real time.

To accomplish this, sponsors need more than dashboards. They need unified, analysis-ready data streams that are continuously monitored. They need automated detection of safety imbalance, enrollment drift, endpoint risk, and operational deviation while corrective options remain viable. They need predictive insights, not retrospective summaries. And they need succinct, interpretable evidence that is defensible in regulatory dialogue.

This is precisely what we designed Vivo to accomplish.

Vivo harmonizes trial data across the clinical ecosystem and applies agentic AI to monitor execution in real time. It surfaces emerging risk, interprets underlying drivers, and enables leadership to make staged, evidence-based decisions inside a compressed development model.

The teams that will lead in a one-trial environment are the ones building continuous intelligence into their operations now. At OmniScience, our mission is to transform clinical trial operations so that life-changing medicines reach patients faster. Vivo is how we deliver on that.

If your organization is preparing for what this shift demands, we would welcome the conversation. Contact us to learn more.